Induction of tolerogenic dendritic cells by a PEGylated TLR7 ligand for treatment of type 1 diabetes

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Hayashi, Tomoko ^a   Yao, Shiyin ^a   Crain, Brian ^a   Promessi, Victor J ^a   Shyu, Luke ^a   Sheng, Caroline ^a   Kang, McNancy ^a   Cottam, Howard B ^a   Carson, Dennis A ^a   Corr, Maripat ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1Z1; ANTIDIABETIC AGENT; B7 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ADOPTIVE TRANSFER; ANIMAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD274; CYTOKINES; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; PHENOTYPE; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 7;

EID: 84953911381     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129867     Document Type: Article

References (59)

1. Mbongue J, Nicholas D, Firek A, Langridge W. The role of dendritic cells in tissue-specific autoimmunity. J Immunol Res. 2014; 2014:857143. Epub 2014/05/31. doi: 10.1155/2014/857143 PMID: 24877157; PubMed Central PMCID: PMC4022068.
2. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. Epub 2003/03/05. doi: 10.1146/annurev.immunol.21.120601.141040 PMID: 12615891.
3. Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev. 2010; 10(1):8-17. Epub 2010/08/04. doi: 10.1016/j.autrev.2010.07.015 PMID: 20678591.
4. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006; 108(5):1435-40. Epub 2006/05/11. doi: 10.1182/blood-2006-03-006403 PMID: 16684955.
5. Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F, et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood. 2006; 107(7):2846-54. Epub 2005/12/13. doi: 10.1182/blood-2005-10-4077 PMID: 16339401.
6. Farias AS, Spagnol GS, Bordeaux-Rego P, Oliveira CO, Fontana AG, de Paula RF, et al. Vitamin D3 induces IDO(+) tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther. 2013; 19(4):269-77. Epub 2013/03/26. doi: 10.1111/cns.12071 PMID: 23521914.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392 (6673):245-52. Epub 1998/04/01. doi: 10.1038/32588 PMID: 9521319.
8. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol. 2009; 39(11):3147-59. Epub 2009/08/19. doi: 10.1002/eji.200839103 PMID: 19688742.
9. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008; 223:271-83. Epub 2008/07/11. doi: 10.1111/j.1600-065X.2008.00630.x PMID: 18613842.
10. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U. S.A. 2003; 100(11):6646-51. PMID: 12738885.
11. Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U.S.A. 2006; 103(6):1828-33. PMID: 16446426.
12. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002; 3(2):196-200. PMID: 11812998.
13. Kurimoto A, Ogino T, Ichii S, Isobe Y, Tobe M, Ogita H, et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorganic & medicinal chemistry. 2004; 12(5):1091-9. PMID: 14980621.
14. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U.S.A. 2009; 106(8):2764-9. Epub 2009/02/04. 0813037106 [pii] doi: 10.1073/pnas.0813037106 PMID: 19188597; PubMed Central PMCID: PMC2634806.
15. Hayashi T, Yao S, Crain B, Chan M, Tawatao RI, Gray C, et al. Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System. PLoS One. 2012; 7(9):e45860. Epub 2012/10/03. doi: 10.1371/journal.pone.0045860 PMID: 23029281; PubMed Central PMCID: PMC3461028.
16. Chan M, Hayashi T, Mathewson RD, Yao S, Gray C, Tawatao RI, et al. Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands. Bioconjug Chem. 2011; 22(3):445-54. Epub 2011/02/23. doi: 10.1021/bc1004813 PMID: 21338093; PubMed Central PMCID: PMC3063487.
17. Hayashi T, S. Y, B. C, Chan M, Cottam HB, Lao F, et al. Mast cell mediated inhibition of abdominal neutrophil inflammation by a PEGylated TLR7 ligand. Mediators Inflamm. 2012;2012. doi: 10.1155/2012/262394
18. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem. 2009; 20(6):1194-200. Epub 2009/05/19. doi: 10.1021/bc900054q PMID: 19445505.
19. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest. 2004; 114(2):270-9. Epub 2004/07/16. doi: 10.1172/JCI21275 PMID: 15254594; PubMed Central PMCID: PMC449749.
20. Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol. 2003; 170(8):4102-10. Epub 2003/04/19. PMID: 12682240.
21. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000; 243(1-2):147-54. Epub 2000/09/15. PMID: 10986412.
22. Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol. 2001;Chapter 15:Unit 15 9. Epub 2008/04/25. doi: 10.1002/0471142735.im1509s24 PMID: 18432739.
23. Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol. 2002; 32(7):2021-30. Epub 2002/07/13. 10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J. PMID: 12115623.
24. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes. 1999; 48(12):2300-8. Epub 1999/12/02. PMID: 10580417.
25. Mukherjee G, Dilorenzo TP. The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol. 2010; 161(2):197-207. Epub 2010/05/25. doi: 10.1111/j.1365-2249.2010.04157.x PMID: 20491789; PubMed Central PMCID: PMC2909402.
26. Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol. 2010; 160(2):207-14. Epub 2009/12/25. doi: 10.1111/j.1365-2249.2009.04082.x PMID: 20030670; PubMed Central PMCID: PMC2857943.
27. Lo J, Clare-Salzler MJ. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev. 2006; 5(6):419-23. Epub 2006/08/08. doi: 10.1016/j.autrev.2005.12.001 PMID: 16890897.
28. Jaen O, Rulle S, Bessis N, Zago A, Boissier MC, Falgarone G. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology. 2009; 126(1):35-44. Epub 2008/08/30. doi: 10.1111/j.1365-2567.2008.02875.x PMID: 18754812; PubMed Central PMCID: PMC2632710.
29. Lan YY, Wang Z, Raimondi G, Wu W, Colvin BL, de Creus A, et al. "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol. 2006; 177(9):5868-77. Epub 2006/10/24. PMID: 17056511.
30. Karumuthil-Melethil S, Perez N, Li R, Vasu C. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J Immunol. 2008; 181(12):8323-34. Epub 2008/12/04. PMID: 19050249; PubMed Central PMCID: PMC2679699.
31. Shiu J, Czinn SJ, Kobayashi KS, Sun Y, Blanchard TG. IRAK-M expression limits dendritic cell activation and proinflammatory cytokine production in response to Helicobacter pylori. PLoS One. 2013; 8(6): e66914. Epub 2013/06/19. doi: 10.1371/journal.pone.0066914 PMID: 23776703; PubMed Central PMCID: PMC3679069.
32. Cole TS, Zhang M, Standiford TJ, Newstead M, Luther J, Zhang J, et al. IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. Immunol Lett. 2012; 144(1-2):49-59. Epub 2012/04/05. doi: 10.1016/j.imlet.2012.03.006 PMID: 22472665; PubMed Central PMCID: PMC3577058.
33. Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, Perone MJ. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clin Exp Immunol. 2013; 171(2):135-46. Epub 2013/01/05. doi: 10.1111/cei.12019 PMID: 23286940; PubMed Central PMCID: PMC3573284.
34. Giannoukakis N, Trucco M. Dendritic cell therapy for Type 1 diabetes suppression. Immunotherapy. 2012; 4(10):1063-74. Epub 2012/11/15. doi: 10.2217/imt.12.76 PMID: 23148758.
35. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol. 2007; 7(8):650-4. Epub 2007/07/27. doi: 10.1038/nri2137 PMID: 17653127.
36. Lewkowicz P, Lewkowicz N, Sasiak A, Tchorzewski H. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol. 2006; 177(10):7155-63. Epub 2006/11/04. PMID: 17082633.
37. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003; 197(4):403-11. Epub 2003/02/20. PMID: 12591899; PubMed Central PMCID: PMC2193858.
38. Filippi CM, Ehrhardt K, Estes EA, Larsson P, Oldham JE, von Herrath MG. TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur J Immunol. 2011; 41(5):1399-409. Epub 2011/04/07. doi: 10.1002/eji.200939841 PMID: 21469083; PubMed Central PMCID: PMC3100206.
39. Kim DH, Lee JC, Lee MK, Kim KW, Lee MS. Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia. 2012; 55(12):3308-17. Epub 2012/09/27. doi: 10.1007/s00125-012-2723-x PMID: 23011352.
40. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006; 203(7):1701-11. Epub 2006/07/05. doi: 10.1084/jem.20060772 PMID: 16818678; PubMed Central PMCID: PMC2118339.
41. Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S, et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol. 2010; 40(9):2528-38. Epub 2010/08/07. doi: 10.1002/eji.201040531 PMID: 20690182.
42. Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008; 15(4):326-31. Epub 2008/07/03. doi: 10.1097/MED.0b013e3283073a46 PMID: 18594272.
43. Kim HS, Lee MS. Role of innate immunity in triggering and tuning of autoimmune diabetes. Curr Mol Med. 2009; 9(1):30-44. Epub 2009/02/10. PMID: 19199940.
44. Diana J, Gahzarian L, Simoni Y, Lehuen A. Innate immunity in type 1 diabetes. Discov Med. 2011; 11(61):513-20. Epub 2011/06/30. PMID: 21712017.
45. Grieco FA, Vendrame F, Spagnuolo I, Dotta F. Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol. 2011; 33(1):57-66. Epub 2010/04/13. doi: 10.1007/s00281-010-0206-z PMID: 20383637.
46. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 2002; 195(1):15-21. Epub 2002/01/10. PMID: 11781361; PubMed Central PMCID: PMC2196016.
47. Arora M, Poe SL, Ray A, Ray P. LPS-induced CD11b+Gr1(int)F4/80+ regulatory myeloid cells suppress allergen-induced airway inflammation. Int Immunopharmacol. 2011; 11(7):827-32. Epub 2011/02/16. doi: 10.1016/j.intimp.2011.01.034 PMID: 21320637; PubMed Central PMCID: PMC3109207.
48. Garate D, Rojas-Colonelli N, Pena C, Salazar L, Abello P, Pesce B, et al. Blocking of p38 and transforming growth factor beta receptor pathways impairs the ability of tolerogenic dendritic cells to suppress murine arthritis. Arthritis Rheum. 2013; 65(1):120-9. Epub 2012/09/14. doi: 10.1002/art.37702 PMID: 22972370.
49. Salazar L, Aravena O, Contreras-Levicoy J, Pesce B, Catalan D, Zuniga R, et al. Short-term lipopolysaccharide stimulation induces differentiation of murine bone marrow-derived dendritic cells into a tolerogenic phenotype. Eur Cytokine Netw. 2007; 18(2):78-85. Epub 2007/06/28. doi: 10.1684/ecn.2007.0089 PMID: 17594940.
50. Kim DH, Lee JC, Kim S, Oh SH, Lee MK, Kim KW, et al. Inhibition of autoimmune diabetes by TLR2 tolerance. J Immunol. 2011; 187(10):5211-20. Epub 2011/10/15. doi: 10.4049/jimmunol.1001388 PMID: 21998452.
51. Mackern-Oberti JP, Vega F, Llanos C, Bueno SM, Kalergis AM. Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci. 2014; 15(9):16381-417. Epub 2014/09/18. doi: 10.3390/ijms150916381 PMID: 25229821; PubMed Central PMCID: PMC4200801.
52. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguia R, Bajana S, Meraz-Rios MA, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol. 2010; 184(4):1765-75. Epub 2010/01/20. doi: 10.4049/jimmunol.0902133 PMID: 20083662.
53. Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes. 2003; 52(8):1976-85. Epub 2003/07/29. PMID: 12882913.
54. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci. 2003; 987:258-61. Epub 2003/05/03. PMID: 12727648.
55. Tochino Y. The NOD mouse as a model of type I diabetes. Crit Rev Immunol. 1987; 8(1):49-81. Epub 1987/01/01. PMID: 2961513.
56. Phillips B, Trucco M, Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol. 2011; 2011:432016. Epub 2011/07/26. doi: 10.1155/2011/432016 PMID: 21785616; PubMed Central PMCID: PMC3139873.
57. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. Epub 2000/03/04. PMID: 10699287.
58. Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov. 2013; 12 (4):306-24. Epub 2013/03/29. doi: 10.1038/nrd3974 PMID: 23535934.
59. Hayashi T, Cottam HB, Chan M, Jin G, Tawatao RI, Crain B, et al. Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. Am J Physiol Regul Integr Comp Physiol. 2008; 295(1):R123-32. Epub 2008/05/16. 00527.2007 [pii] doi: 10.1152/ajpregu.00527.2007 PMID: 18480244; PubMed Central PMCID: PMC2494819.